Selected research
Market Analysis & Forecast
Global Virus Bank Manufacturing Market Analysis and Forecast 2026-2032
Market perspective
The global Virus Bank Manufacturing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Virus Bank Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Virus Bank Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Virus Bank Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Virus Bank Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Virus Bank Manufacturing include Clean Cells, Sigma-Aldrich, ReciBioPharm, ViruSure, Cell and Gene, Naobios, TFBS Bioscience, Inc., Catalent Biologics and SK pharmteco, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Virus Bank Manufacturing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Virus Bank Manufacturing, also provides the revenue of main regions and countries. Of the upcoming market potential for Virus Bank Manufacturing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Virus Bank Manufacturing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Virus Bank Manufacturing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Virus Bank Manufacturing revenue, projected growth trends, production technology, application and end-user industry.
Virus Bank Manufacturing Segment by Company
Clean Cells
Sigma-Aldrich
ReciBioPharm
ViruSure
Cell and Gene
Naobios
TFBS Bioscience, Inc.
Catalent Biologics
SK pharmteco
Charles River Laboratories
SGS SA
Virus Bank Manufacturing Segment by Type
Master Virus Seeds Stocks
Working Virus Seeds Stocks
Virus Bank Manufacturing Segment by Application
Biological Vaccines
Gene Therapy
Others
Virus Bank Manufacturing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus Bank Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus Bank Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus Bank Manufacturing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Virus Bank Manufacturing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Virus Bank Manufacturing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Virus Bank Manufacturing revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Master Virus Seeds Stocks
- Working Virus Seeds Stocks
Applications
- Biological Vaccines
- Gene Therapy
- Others
Companies covered
- Clean Cells
- Sigma-Aldrich
- ReciBioPharm
- ViruSure
- Cell and Gene
- Naobios
- TFBS Bioscience, Inc.
- Catalent Biologics
- SK pharmteco
- Charles River Laboratories
- SGS SA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Virus Bank Manufacturing Market by Type
- 1.2.1 Global Virus Bank Manufacturing Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Master Virus Seeds Stocks
- 1.2.3 Working Virus Seeds Stocks
- 1.3 Virus Bank Manufacturing Market by Application
- 1.3.1 Global Virus Bank Manufacturing Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Biological Vaccines
- 1.3.3 Gene Therapy
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Virus Bank Manufacturing Market Dynamics
- 2.1 Virus Bank Manufacturing Industry Trends
- 2.2 Virus Bank Manufacturing Industry Drivers
- 2.3 Virus Bank Manufacturing Industry Opportunities and Challenges
- 2.4 Virus Bank Manufacturing Industry Restraints
3 Global Growth Perspective
- 3.1 Global Virus Bank Manufacturing Market Perspective (2021-2032)
- 3.2 Global Virus Bank Manufacturing Growth Trends by Region
- 3.2.1 Global Virus Bank Manufacturing Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Virus Bank Manufacturing Market Size by Region (2021-2026)
- 3.2.3 Global Virus Bank Manufacturing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Virus Bank Manufacturing Revenue by Players
- 4.1.1 Global Virus Bank Manufacturing Revenue by Players (2021-2026)
- 4.1.2 Global Virus Bank Manufacturing Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Virus Bank Manufacturing Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Virus Bank Manufacturing Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Virus Bank Manufacturing Key Players Headquarters & Area Served
- 4.4 Global Virus Bank Manufacturing Players, Product Type & Application
- 4.5 Global Virus Bank Manufacturing Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Virus Bank Manufacturing Market CR5 and HHI
- 4.6.3 2025 Virus Bank Manufacturing Tier 1, Tier 2, and Tier 3
5 Virus Bank Manufacturing Market Size by Type
- 5.1 Global Virus Bank Manufacturing Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Virus Bank Manufacturing Revenue by Type (2021-2032)
- 5.3 Global Virus Bank Manufacturing Revenue Market Share by Type (2021-2032)
6 Virus Bank Manufacturing Market Size by Application
- 6.1 Global Virus Bank Manufacturing Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Virus Bank Manufacturing Revenue by Application (2021-2032)
- 6.3 Global Virus Bank Manufacturing Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Clean Cells
- 7.1.1 Clean Cells Company Information
- 7.1.2 Clean Cells Business Overview
- 7.1.3 Clean Cells Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.1.4 Clean Cells Virus Bank Manufacturing Product Portfolio
- 7.1.5 Clean Cells Recent Developments
- 7.2 Sigma-Aldrich
- 7.2.1 Sigma-Aldrich Company Information
- 7.2.2 Sigma-Aldrich Business Overview
- 7.2.3 Sigma-Aldrich Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.2.4 Sigma-Aldrich Virus Bank Manufacturing Product Portfolio
- 7.2.5 Sigma-Aldrich Recent Developments
- 7.3 ReciBioPharm
- 7.3.1 ReciBioPharm Company Information
- 7.3.2 ReciBioPharm Business Overview
- 7.3.3 ReciBioPharm Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.3.4 ReciBioPharm Virus Bank Manufacturing Product Portfolio
- 7.3.5 ReciBioPharm Recent Developments
- 7.4 ViruSure
- 7.4.1 ViruSure Company Information
- 7.4.2 ViruSure Business Overview
- 7.4.3 ViruSure Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.4.4 ViruSure Virus Bank Manufacturing Product Portfolio
- 7.4.5 ViruSure Recent Developments
- 7.5 Cell and Gene
- 7.5.1 Cell and Gene Company Information
- 7.5.2 Cell and Gene Business Overview
- 7.5.3 Cell and Gene Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.5.4 Cell and Gene Virus Bank Manufacturing Product Portfolio
- 7.5.5 Cell and Gene Recent Developments
- 7.6 Naobios
- 7.6.1 Naobios Company Information
- 7.6.2 Naobios Business Overview
- 7.6.3 Naobios Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.6.4 Naobios Virus Bank Manufacturing Product Portfolio
- 7.6.5 Naobios Recent Developments
- 7.7 TFBS Bioscience, Inc.
- 7.7.1 TFBS Bioscience, Inc. Company Information
- 7.7.2 TFBS Bioscience, Inc. Business Overview
- 7.7.3 TFBS Bioscience, Inc. Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.7.4 TFBS Bioscience, Inc. Virus Bank Manufacturing Product Portfolio
- 7.7.5 TFBS Bioscience, Inc. Recent Developments
- 7.8 Catalent Biologics
- 7.8.1 Catalent Biologics Company Information
- 7.8.2 Catalent Biologics Business Overview
- 7.8.3 Catalent Biologics Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.8.4 Catalent Biologics Virus Bank Manufacturing Product Portfolio
- 7.8.5 Catalent Biologics Recent Developments
- 7.9 SK pharmteco
- 7.9.1 SK pharmteco Company Information
- 7.9.2 SK pharmteco Business Overview
- 7.9.3 SK pharmteco Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.9.4 SK pharmteco Virus Bank Manufacturing Product Portfolio
- 7.9.5 SK pharmteco Recent Developments
- 7.10 Charles River Laboratories
- 7.10.1 Charles River Laboratories Company Information
- 7.10.2 Charles River Laboratories Business Overview
- 7.10.3 Charles River Laboratories Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.10.4 Charles River Laboratories Virus Bank Manufacturing Product Portfolio
- 7.10.5 Charles River Laboratories Recent Developments
- 7.11 SGS SA
- 7.11.1 SGS SA Company Information
- 7.11.2 SGS SA Business Overview
- 7.11.3 SGS SA Virus Bank Manufacturing Revenue and Gross Margin (2021-2026)
- 7.11.4 SGS SA Virus Bank Manufacturing Product Portfolio
- 7.11.5 SGS SA Recent Developments
8 North America
- 8.1 North America Virus Bank Manufacturing Revenue (2021-2032)
- 8.2 North America Virus Bank Manufacturing Revenue by Type (2021-2032)
- 8.2.1 North America Virus Bank Manufacturing Revenue by Type (2021-2026)
- 8.2.2 North America Virus Bank Manufacturing Revenue by Type (2027-2032)
- 8.3 North America Virus Bank Manufacturing Revenue Share by Type (2021-2032)
- 8.4 North America Virus Bank Manufacturing Revenue by Application (2021-2032)
- 8.4.1 North America Virus Bank Manufacturing Revenue by Application (2021-2026)
- 8.4.2 North America Virus Bank Manufacturing Revenue by Application (2027-2032)
- 8.5 North America Virus Bank Manufacturing Revenue Share by Application (2021-2032)
- 8.6 North America Virus Bank Manufacturing Revenue by Country
- 8.6.1 North America Virus Bank Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Virus Bank Manufacturing Revenue by Country (2021-2026)
- 8.6.3 North America Virus Bank Manufacturing Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Virus Bank Manufacturing Revenue (2021-2032)
- 9.2 Europe Virus Bank Manufacturing Revenue by Type (2021-2032)
- 9.2.1 Europe Virus Bank Manufacturing Revenue by Type (2021-2026)
- 9.2.2 Europe Virus Bank Manufacturing Revenue by Type (2027-2032)
- 9.3 Europe Virus Bank Manufacturing Revenue Share by Type (2021-2032)
- 9.4 Europe Virus Bank Manufacturing Revenue by Application (2021-2032)
- 9.4.1 Europe Virus Bank Manufacturing Revenue by Application (2021-2026)
- 9.4.2 Europe Virus Bank Manufacturing Revenue by Application (2027-2032)
- 9.5 Europe Virus Bank Manufacturing Revenue Share by Application (2021-2032)
- 9.6 Europe Virus Bank Manufacturing Revenue by Country
- 9.6.1 Europe Virus Bank Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Virus Bank Manufacturing Revenue by Country (2021-2026)
- 9.6.3 Europe Virus Bank Manufacturing Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Virus Bank Manufacturing Revenue (2021-2032)
- 10.2 China Virus Bank Manufacturing Revenue by Type (2021-2032)
- 10.2.1 China Virus Bank Manufacturing Revenue by Type (2021-2026)
- 10.2.2 China Virus Bank Manufacturing Revenue by Type (2027-2032)
- 10.3 China Virus Bank Manufacturing Revenue Share by Type (2021-2032)
- 10.4 China Virus Bank Manufacturing Revenue by Application (2021-2032)
- 10.4.1 China Virus Bank Manufacturing Revenue by Application (2021-2026)
- 10.4.2 China Virus Bank Manufacturing Revenue by Application (2027-2032)
- 10.5 China Virus Bank Manufacturing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Virus Bank Manufacturing Revenue (2021-2032)
- 11.2 Asia Virus Bank Manufacturing Revenue by Type (2021-2032)
- 11.2.1 Asia Virus Bank Manufacturing Revenue by Type (2021-2026)
- 11.2.2 Asia Virus Bank Manufacturing Revenue by Type (2027-2032)
- 11.3 Asia Virus Bank Manufacturing Revenue Share by Type (2021-2032)
- 11.4 Asia Virus Bank Manufacturing Revenue by Application (2021-2032)
- 11.4.1 Asia Virus Bank Manufacturing Revenue by Application (2021-2026)
- 11.4.2 Asia Virus Bank Manufacturing Revenue by Application (2027-2032)
- 11.5 Asia Virus Bank Manufacturing Revenue Share by Application (2021-2032)
- 11.6 Asia Virus Bank Manufacturing Revenue by Country
- 11.6.1 Asia Virus Bank Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Virus Bank Manufacturing Revenue by Country (2021-2026)
- 11.6.3 Asia Virus Bank Manufacturing Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Virus Bank Manufacturing Revenue (2021-2032)
- 12.2 SAMEA Virus Bank Manufacturing Revenue by Type (2021-2032)
- 12.2.1 SAMEA Virus Bank Manufacturing Revenue by Type (2021-2026)
- 12.2.2 SAMEA Virus Bank Manufacturing Revenue by Type (2027-2032)
- 12.3 SAMEA Virus Bank Manufacturing Revenue Share by Type (2021-2032)
- 12.4 SAMEA Virus Bank Manufacturing Revenue by Application (2021-2032)
- 12.4.1 SAMEA Virus Bank Manufacturing Revenue by Application (2021-2026)
- 12.4.2 SAMEA Virus Bank Manufacturing Revenue by Application (2027-2032)
- 12.5 SAMEA Virus Bank Manufacturing Revenue Share by Application (2021-2032)
- 12.6 SAMEA Virus Bank Manufacturing Revenue by Country
- 12.6.1 SAMEA Virus Bank Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Virus Bank Manufacturing Revenue by Country (2021-2026)
- 12.6.3 SAMEA Virus Bank Manufacturing Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst